their biological behavior has not fully been elucidated, and the management has not been optimized. In the present study, we analyzed non-invasive recurrences after bladder-preserving therapy for invasive bladder cancer.
INTRODUCTION AND OBJECTIVES:
To determine the effect of neoadjuvant chemotherapy (NAC) on surgical outcomes in patients undergoing laparoscopic radical nephroureterectomy (LNUX) for upper urinary tract urothelial carcinoma (UTUC).
METHODS: We performed a retrospective review of all UTUC patients who underwent LNUX performed at our institution between 1/2003 and 6/2010. Patients with high-grade tumor on biopsy and large tumor volume, sessile tumor, or status post cystectomy were considered high-risk and recommended to undergo NAC. High risk patients also underwent lymphadenectomy whether or not chemotherapy was given. A standard laparoscopic approach was undertaken in all cases with a Gibson incision used for dissection of the distal ureter and bladder cuff and intact specimen extraction. We compared differences in demographic, clinicopathological, and operative parameters between patients who underwent LNUX after NAC and patients who underwent initial LNUX. Logistic regression analysis was performed to identify predictors of complications.
RESULTS: We identified 82 UTUC patients who underwent LNUX; 26 received NAC. Patients who underwent LNUX after NAC had a higher body mass index, higher biopsy tumor grade (as expected based on selection criteria), and longer operative time than patients who underwent LNUX without NAC. Patients who received NAC underwent regional lymphadenectomy more often, with more lymph nodes (median number of nodes removed 7.5 vs 4, pϭ0.009) and lymphoadipose tissue removed (median 34.1 cm 3 vs 7.7, pϭ0.002), than patients who did not receive NAC. NAC resulted in a 15% complete remission rate. No differences in median estimated blood loss, intraoperative transfusions, and length of hospitalization between the two groups were found. Perioperative complication rates were similar in both groups.
CONCLUSIONS: Aside from a longer operative time likely as a result of a regional lymphadenectomy, we found no differences in surgical outcomes between patients who underwent LNUX after NAC and patients who underwent LNUX without NAC. The neoadjuvant approach resulted in a 15% rate of complete remission, similar to recently published data on UTUC that also reported a 43% reduction in stage T3-T4 disease. Our findings support the use of LNUX in selected patients undergoing neoadjuvant chemotherapy for UTUC.
Source of Funding:
This study was supported in part by the National Institutes of Health Grant CA091846-08 and Cancer Center Support Grant CA 016672.
PUTATIVE CANCER STEM CELLS (CSCS) SIGNALING AFTER IMMUNOTHERAPY WITH BACILLUS CALMETTE-GUERIN (BCG) AND P-MAPA IN THE SUPERFICIAL BLADDER CANCER (SBC)
Leonardo Reis*, Ubirajara Ferreira, Athanase Billis, Campinas -SP, Brazil; Amanda Castello, Botucatu, Brazil; Iseu Nunes, Nelson Durá n, Valé ria Cagnon, Campinas -SP, Brazil; Wagner Fá varo, Botucatu, Brazil INTRODUCTION AND OBJECTIVES: High recurrence rate and heterogeneous presentation of SBC prompted us to suppose that stem cells could be involved. Intravesical BCG is considered the most successful treatment for SBC. The extracellular purified compound isolated from Aspergillus oryzae was characterized as an aggregated polymeric form of protein magnesium ammonium phospholinoleatepalmitoleate anhydride (P-MAPA), having significant in vivo antitumor and antibacterial activities and no toxicity. The aims of this work were to characterize the putative CSCs features in the SBC of rats submitted to intravesical immunotherapy, and to establish the response of these cells to BCG and P-MAPA.
METHODS: Thirty female Fisher 344 (7 week old) rats were anesthetized and received 1.5 mg/kg dose of n-methyl-n-nitrosourea (MNU), intravesically every other week for 7 weeks. After MNU treatment, the 30 rats were divided into 3 groups: The MNU group received 0.30 ml dose of 0.9% physiological saline; The BCG group received 10 6 UFC dose of BCG; The P-MAPA group received 5 mg/kg dose of P-MAPA, all intravesically for 8 weeks. After 15 weeks, all bladders were collected for immunological and Western Blotting analysis for CD44, CD133, CD117, CK5, ATP-binding cassette membrane transporter (ABCG2), p53, Toll-Like Receptor (TLR) 2 and 4, Ki-67 (cellular proliferation) and apoptosis detection.
RESULTS: CSCs were ABCG2/CD44/CD133ϩ, which were more often in the MNU group and decreased in the BCG and P-MAPA groups. Also, normal urothelial stem cells (USCs) CD44/CD133/ CD117/p53/CK5ϩ were mainly increased in the P-MAPA group. The p53 immunoreactivity was 5% staining of urothelial cells in the MNU group, 20% in the BCG group and Ͼ 50% in the P-MAPA group. The TLR 2 and 4 immunoreactivities were 2% staining of urothelial cells in the MNU group, 11% in the BCG group and Ͼ 50% in the P-MAPA group. The apoptosis and cellular proliferation indexes were increased in all experimental groups. However, these processes were decreased in the BCG and P-MAPA groups in relation to the MNU group (pϽ0.05).
CONCLUSIONS: BCG and P-MAPA showed involvement in the regulation of the p53, TLRs, apoptosis and cellular proliferation balance. However, P-MAPA was more sensitive in restoring p53 and TLRs immunoreactivities and balance between normal USCs and CSCs. P-MAPA therapy showed stimulatory effect on TLRs and p53 RESULTS: B7-DCIg enhanced BCG-induced splenocyte IFN-␥ production in a dose-dependent manner in vitro. B7-DCIg also enhanced BCG-induced bladder expression of IFN-␥ and tumor necrosis factor related apoptosis-inducing ligand (TRAIL) mRNAs in vivo. In the orthotopic tumor model, BCG treatment reduced bladder weight by 53% (p ϭ 0.0503 vs. PBS-treated group). Combination of BCG with B7-DCIg further reduced bladder weight by 5% (p ϭ 0.0257 vs. PBStreated group). In addition, the combination treatment also led to a delay in tumor growth by bioluminescence compared to BCG-treated group.
CONCLUSIONS: B7-DCIg enhanced BCG-induced Th1 and anti-bladder cancer immune responses in mice. B7-DCIg may serve as a potential agent in combination with BCG for the treatment of bladder cancer in humans. INTRODUCTION AND OBJECTIVES: Donor nephrectomy with laparo-endoscopic single site (LESS) surgery has been reported via the transperitoneal approach. The umbilicus (e-NOTES) is a popular site, but leaves a nasty scar and extraction of the kidney may be complex risking warm ischemic renal injury. Our units have a combined experience of around 300 retroperitoneal donor nephrectomies and therefore want to offer single site surgery to our patients.
Source of Funding
METHODS: We describe a novel technique of LESS retroperitoneal donor nephrectomy using a single surgical incision in the groin, below the abdominal skin crease or "bikini line" using a GelportTM and bariatric/curved laparoscopic instruments. The LESS groin incision offers superior cosmesis, while the retroperitoneal approach has distinct advantages, such as the ability to identify the renal vessels early and not violating the peritoneal cavity. The new procedure has been performed in two patients on the right side(body mass index 32 and 33 kg/m2, respectively).
RESULTS: The operative times were 4 and 5 hours, warm ischemic times 135 and 315 seconds, blood loss 100 and 250 ml, and hospitalization 3 and 2 days, respectively. Graft function was good during the early post-operative period.
CONCLUSIONS: Retroperitoneal LESS donor nephrectomy through a single, inconspicuous groin incision is feasible and safe. Further evaluation of the technique in a larger patient cohort is indicated and underway.
Source of Funding: None

V494 ROBOTIC LIVE DONOR NEPHRECTOMY: FIRST EXPERIENCE AT A TERTIARY CENTER
Alberto Breda*, Ernesto Cordeiro, Lluís Gausa, Antonio Rosales, Humberto Villavicencio, Barcelona, Spain INTRODUCTION AND OBJECTIVES: We herein describe our initial experience with an entirely robotic-assisted laparoscopic live donor nephrectomy (RALDN). As far as our knowledge this represents also the first experience in Spain.
METHODS: A 45 year old man was found to be a perfect match to his 44 year old spouse, who was affected by renal insufficiency due to diabetes and high blood pressure. The steps of the robot assisted live donor nephrectomy are herein described and include: 1. Mobilization of the colon down to the level of the iliac vessels 2. Complete mobilization of the spleen to the crus of the diaphragm, 3. Dissection of the adrenal gland and mobilization of the upper pole of the kidney 4. Identification of the renal hilum and gonadal vein 5. Transection of the gonadal vein 2.5 cm from the renal vein 6. Identification of the ureter and dissection between the gonadal vein and the ureter to the level of the common iliac artery 7. Elevation of the kidney and posterior dissection with identification of the renal artery 8. Dissection of the lateral attachment of the kidney 9. Pfannestil incision and insertion of a 15 mm trocar 10. Stapling of the renal artery, renal vein and ureter through the 15 mm trocar 11. Extraction of the specimen with a 15 mm endo-bag.
RESULTS: The procedure was entirely performed with the robotic assistance. The operative time was 145 min. The warm isch-
